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A minor, Le’blood-group inactive ceramide pentasaccharide double band fraction has been isolated from 
the plasma of blood group 0 Le(a-b-) nonsecretors. The two purified glycolipids were analysed by NMR 
spectroscopy, mass spectrometry and combined gas chromatography-mass pectrometry. The following 
structures could be established: GlcNAc(Bl-+3)Gal(j?1 --t4)Glc(Bl -+l)Cer (I); Gal@1 -4) 
[Fuc(al-+3)]GlcNAc(~l-~3)Gal(B1 -+4)Glc(Bl --t l)Cer (II). It must be concluded that at least part of 
the secretor gene-independent plasmatic H type 2 blood-group activity can be attributed to glyco- 
sphingolipid I, whereas substance II, originally detected in cancerous tissue, also occurs in the plasma of 
healthy individuals. 
Blood group Glycosphingolipid Human plasma Lewis negative (non)secretor 
1. INTRODUCTION 
The Lea, Leb and Led (H type 1) blood-group 
active glycosphingolipids of human erythrocytes 
and plasma have been identified in [l-5]. The Le’ 
property has hitherto been defined only by agglu- 
tination of Le(a-b-) erythrocytes of adult 
nonsecretors with appropriate antisera of human 
[6] or goat [7] origin. It has been suggested that the 
LeC antigens are represented by either lacto-ZV- 
fucopentaosyl (III)- [6,8], or unsubstituted lacto- 
N-tetraosyl-oligosaccharides [9]. Immunochemical 
+ To whom correspondence should be addressed 
Abbreviations: Abbreviations and trivial names are 
essentially the same as in [3]: Ga1@31-+4)[Fuc(cu1--+3)] 
GlcNAc@1--+3)GalQTl-+4)Glc, lacto-ilr-fucopen- 
taose III [ 191; Fuc(cul-2)[Gal~l-+4)1GlcNAc~l 
--+3)Gal(81--+4)Glc, lacto-N-fucopentaose IV; amu, 
atomic mass units 
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studies, however, excluded this correlation, since 
corresponding glycolipids failed to react with the 
above-mentioned antisera [lo]. During the course 
of our studies on the isolation and characterization 
of LeC active glycosphingolipids from the plasma 
of Le(a-b-) nonsecretors (in preparation) we iden- 
tified a fraction containing two fucolipids with a 
chromatographical migration behaviour similar to 
that of Lea or Led (H type 1) active 
glycosphingolipids. This paper describes the isola- 
tion and complete immuno- and physicochemical 
characterization of these two fucolipids by means 
of haemagglutination inhibition tests, ‘H NMR, 
fast atom bombardment (FAB) and electron im- 
pact (EI) mass spectrometry and combined gas 
chromatography-mass spectrometry (GC-MS). 
The resulting structures allow conclusions to be 
drawn with regard to the interrelationships of the 
ABH-, Lewis and secretor/nonsecretor blood- 
group systems. 
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2. EXPERIMENTAL 
2.1. Materials 
Glycosphingolipids as reference substances and 
an Ulex europaeus lectin preparation were essen- 
tially the same as in [3]. Human anti-Let (‘ARM’) 
[6] was a generous gift from Dr R.J. Crawford 
(Glasgow and West of Scotland Blood Transfusion 
Service, Carluke, Scotland) and goat anti-LeC [7] 
was obtained from Dr H.A. Graham (Ortho 
Diagnostic Systems Inc., Raritan, NJ). 
2.2. Isolation and purificakon of glycosphingo- 
lipids 
Plasma (15 1) collected from 5 blood-group 0 
Le(a-b-) nonsecretor individuals by repeated 
plasmapheresis was lyophilized and stored until 
use. The isolation procedure was described 
previously [ 1,3]. Purification was completed by 
preparative silica gel HPTLC [l] of the 
peracetylated glycolipids on 20 x 20 plates using 
dichloromethane-methanol-water (97 : 3 : 0.2, 
v/v) as solvent system followed by deacetylation 
bll. 
2.3. Biological assays 
Serological activities against anti-LeC sera and 
U. europaeus lectin were tested by the haemag- 
glutination inhibition test [ 1,2,12]. LeC reactivity 
was also checked by the passive haemagglutination 
technique as in [1,2,12]. 
2.4. Methylation analysis 
Permethylation of glycosphingolipids, subse- 
quent derivatization to partially methylated 
neutral and amino alditol acetates and their 
analysis by GC and combined GC-MS using 3% 
ECNSS-M and 3% OV-225 columns and a 
GC-MS system Model 3100 D (Finnigan) were 
performed as in [13,14]. 
2.5. Fast atom bombardment and electron impact 
mass spectrometry 
FAB, EI mass spectrometry [15] and ‘H NMR 
[16] were performed as described. 
3. RESULTS 
The purified glycolipids I (205 pg) and II 
(195 pg) were homogeneous by criteria of HPTLC, 
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MS and NMR. Up to 5Opg of the glycolipid frac- 
tion containing both components I and II failed to 
inhibit the agglutination of 0 Le(a-b-) 
erythrocytes by both anti-Let antisera used here. 
Also, the same amount did not confer any Le’ an- 
tigenicity on 0 Leb erythrocytes as tested by 
passive haemagglutination. When tested against U. 
europaeus lectin, 8 pg glycolipid I completely in- 
hibited 4 haemagglutinating units whereas 20 pg 
glycolipid II did not effect a complete or even par- 
tial inhibition. Analysis of the partially methylated 
alditol acetates after permethylation, hydrolysis, 
reduction and acetylation by combined GC-MS 
furnished for both glycolipids (I and II), in 
equimolar ratio, derivatives of terminal fucose, 
Fig.1. Silica gel high-performance thin-layer 
chromatography of ceramide pentasaccharides from the 
plasma of 0 Le(a-b-) nonsecretors. (a) Native 
glycolipids (solvent system A) developed in 
chloroform-methanol-water (60: 35 : 8, v/v). (b) 
Peracetylated glycolipids developed in 1,2-dichloro- 
ethane-methanol-water (97 : 3 : 0.2, v/v). Lanes: (1,3) 
glycolipid I, i.e., lacto-N-fucopentaosyl(IV)ceramide; 
(2,4) glycolipid II, i.e., lacto-N-fucopentaosyl(II1) 
ceramide. 
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3-O-substituted galactose and 4-O-substituted 
glucose. Both substances differed however, from 
each other in the presence of 1 mol of a 2-0- 
substituted galactose and a 4-O-substituted N- 
acetylglucosamine in the case of glycolipid I, and 
a terminal galactose and a 3,4-di-O-substituted N- 
acetylglucosamine in the case of glycolipid II. Fur- 
ther evidence for these structures was obtained by 
mass spectrometry and high-resolution ‘H NMR. 
In agreement with the structure of a ceramide pen- 
tasaccharide, the FAB MS of both permethylated 
glycolipids showed intense pseudomolecular ions 
M+H+ at 1611 amu and M+Na+ at 1633 amu. In 
both cases, the ceramide residue was represented 
by an ion at 548 amu. The terminal tri- and tetra- 
saccharide units gave rise to ions at m/z 638 and 
842, but with different intensities and with a diffe- 
rent set of daughter ions. The structural differen- 
ces between both glycolipids were reflected more 
markedly in the EI MS spectra as shown in 
fig.2a,b. In both spectra, the palmitic acid present 
in the ceramide residue is represented by m/z 294 
and the sphingosine by m/z 364. The major ions 
derived from the carbohydrate moiety are in 
perfect agreement with the proposed structures as 
indicated in the schemes of fragmentation. The 
daughter ions m/z 182 in glycolipid I and m/z 432 
in glycolipid II clearly indicate the presence of type 
2 chains in both compounds [171. The different site 
of linkage of the fucose residue gives rise to addi- 
tional specific rearrangement ions such as m/z 
1465 in (I) or m/z 432 and 1169 in (II). 
Using NMR, we have shown that the linkage and 
sequence analysis of peracetylated oligosac- 
charides [ 16,181 and glycosphingolipids 1191 is a 
straightforward procedure thanks to the large up- 
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Fig.2. Electron impact mass spectra of permethylated glycolipids I and II. Ionization energy, 25 eV; accelerating 
voltage, 8 kV; sample and ion source temperature, 270°C. 
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field chemical shifts observed for protons at 
glycosylated carbons vs those at acetoxylated ones. 
Spin-decoupling difference spectra showed that in 
glycolipid I the H-2 signal of Gal-&occurs at 
3.84 ppm (fig.3b) whereas that of Gal&is located 
at 5.00 ppm (fig.3c). Therefore, fucose is obvious- 
ly l-2 linked to Gal& 
It can be demonstrated in a similar manner that 
it is the GlcNAc residue in glycolipid II (fig.3d) 
that is glycosylated by fucose. The GlcNAc H-3 
and H-4 resonances are highfield shifted by 1.21 
and 1.25 ppm, respectively, if compared with 
those of the terminal GlcNAc residue of a related 
glucosaminyl lactitol (GL; table 1) [16], thus 
uh ambiguously indicating the two glycosylation 
positions. The problem of whether fucose is linked 
to site 3 and galactose to site 4, or the reverse, can 
be elucidated by comparing GlcNAc chemical 
shifts for glycolipid II with those of the two 
isomeric fucopentaitols, fucopentaose-III [20] and 
fucopentaose-II [16] (table 1). Most of these 
chemical shifts for glycolipid II and fucopentaose- 
III are either identical or differ only slightly 
whereas a number of values for fucopentaose-II 
deviate much more. Accordingly, glycolipid II and 
fucopentaose-III are ascribed the same partial 
sequence: 
Gal@1 -4)[Fuc(~l-3)]GlcNAc@31-+ ) 
Table 1 
GlcNAc proton chemical shifts (ppm from Me&i, in 
CDC13) of CL-II, GLb, FP-IIIC and FP-IId 
CL-II CL FP-III FP-II 
H-l 4.96 5.05 4.99 4.97 
H-2 3.05 3.30 3.05 3.05 
H-3 4.29 5.50 4.30 4.37 
H-4 3.80 5.05 3.79 3.74 
H-5 3.43 3.68 3.43 3.50 
H-6 3.94 4.08 3.93 3.74 
H-6’ 4.99 4.36 4.94 4.80 
N-H 5.32 5.38 5.41 5.53 
a Peracetylated Gal~l--+4)[Fuc(cu1--+3)]GlcNAc- 
co1 -+3)Gal~1--+4)Glc~1--+ I)Cer 
b Peracetylated GlcNAc@31-+3)Gal@31-4)Glc-01. 
Data from [16] 
’ Peracetylated Gal~1--+4)[Fuc(c~l-+ 3)]GlcNAc- 
Cal --+3)Gal@31-+4)Glc-01. Data from [20] 
d Peracetylated Gal(@ -3)[Fuc(cul-4)]GlcNAc- 
~1--+3)Gal~l-+4)Glc-01. Data from [16] 
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Fig.3. The sugar proton region of the resolution-en- 
hanced 360 MHz ‘H NMR spectra of the ceramide 
fucopentaoses I (a) and II (d), and of the spin- 
decoupling difference spectra (b,c,e) referred to in the 
text (irradiation by a second radiofrequency field is 
indicated by arrows). 
All these results are in accordance with a blood- 
group H type 2 active lacto-N-fucopentaosyl (IV) 
ceramide substance I and a lacto-N-fucopentaosyl 
(III) ceramide for substance II. 
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4. DISCUSSION 
Our first objective was to confirm that 
glycolipids comprising up to 5 sugar units do not 
represent the molecular basis of the LeC antigenici- 
ty. Instead, traces of more complex, neutral 
glycosphingolipids isolated simultaneously from 
the same plasma source showed very strong in- 
hibitory properties of both Le’ and anti-sera’. In 
contrast to Le’, which is characteristically found 
only in the plasma of nonsecretors [21], the biosyn- 
thesis of the identified structures is obviously in- 
dependent of the secretor status of an individual 
[22,23]. Furthermore, the presence of H type 1 
(Led”) ceramide pentasaccharide in the plasma of 
blood-group 0, Lewis negative nonsecretors could 
also be excluded by physicochemical means. It can 
be concluded that, in contrast to H type 1 struc- 
tures, at least a part of the plasmatic H type 2 an- 
tigens can be synthesized independently of the in- 
fluence of the secretor gene. Previous determina- 
tions by radioimmunoassay of H type 1 and 2 
blood-group activities of human sera from dif- 
ferent secretor phenotypes confirm our findings 
(22). This paper additionally reveals that the secre- 
tor gene-independent H type 2 antigenicity of 
plasma has, at least in part, to be ascribed to glyco- 
sphingolipids. 
Lacto-N-fucopentaosyl (III) structures have 
been designated as the Le” antigen [24]. However, 
anti-LeX does not react with red cells of all 
Le(a-b-) individuals [25]. Furthermore, the LeX 
property is rather based on a particular specificity 
of the anti-LeX antibodies reacting with the 
Fuc(~l---+4)GlcNAc region of both the Le” and 
Leb antigenic determinants [26]. Thus, it is sug- 
gested to return to the former designation of the 
‘X-antigenic’ determinant for all Gal@1 -4) 
[Fuc(~l--+3)]GlcNAc residues. The X-antigen 
has originally been regarded as a tumor-associated 
cell surface marker [27]. In fact, many antibodies 
produced by hybridomas obtained from mice im- 
munized with human adenocarcinomas of colon, 
stomach, or lung are directed against a sugar se- 
quence found in lacto-N-fucopentaose III [28]. 
However, analogous structures also occur in non- 
cancerous tissues or body fluids of healthy individ- 
uals, such as human erythrocytes 1241, granulo- 
cytes and granulocyte precursor cells 1281 or in 
human milk [23], irrespective of the secretor or 
nonsecretor status of the individual from whom 
the substances have been isolated. This paper 
reveals its additional occurrence in human plasma 
although in minor amounts. Further studies on the 
quantity of this structure in different human 
tissues and sources are necessary to define more ex- 
actly the behaviour of this antigen during develop- 
ment, and differentiation as has been done for the 
analogous stage specific embryonic SSEA-1 an- 
tigen in mice [30]. 
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